Literature DB >> 2559337

Effects of adenosine analogues on contractile response and cAMP content in guinea-pig isolated ventricular myocytes.

J Neumann1, W Schmitz, H Scholz, B Stein.   

Abstract

In the present study the effects of adenosine analogues were investigated on cAMP content and contractile response in guinea-pig ventricular myocytes. The adenosine analogues (-)-N6-phenylisopropyladenosine (R-PIA), 5'-N-ethylcarboxamideadenosine (NECA) and (+)-N6-phenylisopropyladenosine (S-PIA) in the presence of 0.01 mumol/l isoprenaline reduced contractile response concentration-dependently. R-PIA and NECA were about equipotent (IC25: 0.01 mumol/l and 0.039 mumol/l respectively), while S-PIA was less potent (IC25: 0.6 mumol/l). Isoprenaline stimulated cAMP content was reduced by R-PIA (IC25: 0.004 mumol/l) and with lower potency by S-PIA (IC25: 0.15 mumol/l), but the extent of reduction of cAMP by R-PIA and S-PIA (to 55% and 64% respectively) was less than the reduction of contractile response (to 26% and 55% respectively). This suggests that the effects of R- and S-PIA on contractile response are only in part due to a reduction in cAMP content. In addition, NECA did not decrease cAMP content but decreased contractile response to the same extent as R-PIA. Similar results were obtained in the presence of the phosphodiesterase inhibitor Ro 20-1724. Time course studies revealed that the effects of R-PIA (1 mumol/l) on cAMP content and contractile response coincided reaching steady state after 5 min and remained stable thereafter. The effects of NECA (1 mumol/l) on contractility also reached steady state within 5 min, whereas it did not change cAMP content. It is concluded that the reduction of contractility by adenosine analogues in the presence of isoprenaline can only in part be explained by a reduction of cAMP content.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2559337     DOI: 10.1007/BF00717746

Source DB:  PubMed          Journal:  Naunyn Schmiedebergs Arch Pharmacol        ISSN: 0028-1298            Impact factor:   3.000


  34 in total

1.  Reduction by adenosine of the isoproterenol-induced increase in cyclic adenosine 3',5'-monophosphate formation and glycogen phosphorylase activity in rat heart muscle.

Authors:  J G Dobson
Journal:  Circ Res       Date:  1978-11       Impact factor: 17.367

2.  Adenosine as inhibitor of myocardial effects of catecholamines.

Authors:  J Schrader; G Baumann; E Gerlach
Journal:  Pflugers Arch       Date:  1977-11-25       Impact factor: 3.657

3.  Interaction between adenosine and catecholamines on cyclic AMP accumulation in guinea pig ventricular myocardium.

Authors:  M Huang; G I Drummond
Journal:  Biochem Pharmacol       Date:  1978-01-15       Impact factor: 5.858

4.  Regulation of adenylate cyclase in cultured cardiocytes from neonatal rats by adenosine and other agonists.

Authors:  M B Anand-Srivastava; M Cantin
Journal:  Arch Biochem Biophys       Date:  1983-06       Impact factor: 4.013

5.  Subclasses of external adenosine receptors.

Authors:  C Londos; D M Cooper; J Wolff
Journal:  Proc Natl Acad Sci U S A       Date:  1980-05       Impact factor: 11.205

6.  Calcium tolerant ventricular myocytes prepared by preincubation in a "KB medium".

Authors:  G Isenberg; U Klockner
Journal:  Pflugers Arch       Date:  1982-10       Impact factor: 3.657

7.  Adenosine inhibition of catecholamine-stimulated cardiac membrane adenylate cyclase.

Authors:  D A LaMonica; N Frohloff; J G Dobson
Journal:  Am J Physiol       Date:  1985-05

8.  Adenosine inhibition of catecholamine-induced increase in force of contraction in guinea-pig atrial and ventricular heart preparations. Evidence against a cyclic AMP- and cyclic GMP-dependent effect.

Authors:  M Böhm; R Brückner; I Hackbarth; B Haubitz; R Linhart; W Meyer; B Schmidt; W Schmitz; H Scholz
Journal:  J Pharmacol Exp Ther       Date:  1984-08       Impact factor: 4.030

9.  Solid phase radioimmunoassay for cyclic AMP using staphylococcal protein A-antibody adsorbent.

Authors:  C J Struck; G Ahnert; H Glossmann; W Schaeg
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1977-05       Impact factor: 3.000

10.  Actions of adenosine and isoproterenol on isolated mammalian ventricular myocytes.

Authors:  L Belardinelli; G Isenberg
Journal:  Circ Res       Date:  1983-09       Impact factor: 17.367

View more
  5 in total

1.  Negative chronotropic and inotropic effects exerted by diadenosine hexaphosphate (AP6A) via A1-adenosine receptors.

Authors:  U Vahlensieck; P Bokník; J Knapp; B Linck; F U Müller; J Neumann; S Herzig; H Schlüter; W Zidek; M C Deng; H H Scheld; W Schmitz
Journal:  Br J Pharmacol       Date:  1996-11       Impact factor: 8.739

2.  Pharmacological characteristics of adenosine-induced inhibition of dog ventricular contractility: dependence on the pre-existing level of beta-adrenoceptor activation.

Authors:  M Endoh; H Kushida; I Norota; M Takanashi
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1991-07       Impact factor: 3.000

3.  PACAP induces bradycardia in guinea-pig heart by stimulation of atrial cholinergic neurones.

Authors:  J Seebeck; W E Schmidt; H Kilbinger; J Neumann; N Zimmermann; S Herzig
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1996-10       Impact factor: 3.000

4.  Stimulation of protein phosphatases as a mechanism of the muscarinic-receptor-mediated inhibition of cardiac L-type Ca2+ channels.

Authors:  S Herzig; A Meier; M Pfeiffer; J Neumann
Journal:  Pflugers Arch       Date:  1995-02       Impact factor: 3.657

5.  Phenotyping of Mice with Heart Specific Overexpression of A2A-Adenosine Receptors: Evidence for Cardioprotective Effects of A2A-Adenosine Receptors.

Authors:  Peter Boknik; Katharina Drzewiecki; John Eskandar; Ulrich Gergs; Stephanie Grote-Wessels; Larissa Fabritz; Paulus Kirchhof; Frank U Müller; Frank Stümpel; Wilhelm Schmitz; Norbert Zimmermann; Uwe Kirchhefer; Joachim Neumann
Journal:  Front Pharmacol       Date:  2018-01-22       Impact factor: 5.810

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.